Overview Phio Pharmaceuticals Corp. ( Phio , we , our or the Company ) is a clinical stage biopharmaceuticalcompany whose proprietary INTASYL small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the bodys ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are commi...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001437749-26-007078 | EDGAR | 47K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002134 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002021 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001678 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001833 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001683168-21-001062 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000969 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001683168-19-000795 | EDGAR | — |
| 2018-03-26 | 2017-12-31 | 0001193125-18-096053 | EDGAR | — |
| 2017-03-30 | 2016-12-31 | 0001193125-17-102730 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001437749-26-026271 | EDGAR | — |
| 2025-11-13 | 2025-09-30 | 0001437749-25-034857 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006174 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003719 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008120 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005706 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003175 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007809 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005514 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003213 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007528 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005565 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001437749-26-026275 | EDGAR | — |
| 2026-07-21 | 0001437749-26-023916 | EDGAR | — |
| 2026-03-30 | 0001437749-26-010164 | EDGAR | 1K words |
| 2026-03-05 | 0001437749-26-007071 | EDGAR | — |
| 2026-02-18 | 0001437749-26-004542 | EDGAR | — |
| 2026-02-10 | 0001437749-26-003575 | EDGAR | — |
| 2026-01-20 | 0001437749-26-001500 | EDGAR | — |
| 2025-12-23 | 0001437749-25-038607 | EDGAR | — |
| 2025-11-25 | 0001437749-25-036329 | EDGAR | — |
| 2025-11-13 | 0001437749-25-034848 | EDGAR | — |
330 total filings indexed. 298 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001533040 |
| Ticker | PHIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.phiopharma.com |
| Listed | 2012-05-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PHIO (~200 tokens, structured JSON with cryptographic provenance)